Trevogrumab

Last updated

Trevogrumab
Monoclonal antibody
Type ?
Source Human
Target growth differentiation factor 8
Clinical data
Other namesREGN1033
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6374H9884N1696O2018S46
Molar mass 144037.80 g·mol−1

Trevogrumab (INN; [1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. Sometimes it is combined with Garetosmab.

Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin (GDF8), a key negative regulator of skeletal muscle growth and mass. By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation. [2]

This drug was developed by Regeneron Pharmaceuticals, Inc. [3]

References

  1. ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. ↑ Mastaitis JW, Gomez D, Raya JG, Li D, Min S, Stec M, et al. (May 2025). "GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates". Nature Communications. 16 (1) 4377. Bibcode:2025NatCo..16.4377M. doi:10.1038/s41467-025-59485-9. PMC   12075787 . PMID   40360507.
  3. ↑ "Trevogrumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.